# Sarepta Therapeutics, Inc.: financial statements, quarterly

SRPT · Nasdaq · CIK 873303 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/srpt.md) · [Financials](/companies/srpt/financials.md) · [Filings](/companies/srpt/filings.md) · [Insiders](/companies/srpt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/srpt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [309](/filings/0000950170-24-122239.md) | [365 d](/filings/0001193125-26-084144.md) | [359](/filings/0000950170-25-064412.md) | [361](/filings/0000950170-25-103971.md) | [430](/filings/0001193125-25-269436.md) | [658](/filings/0001193125-26-084144.md) | [612](/filings/0001193125-26-208893.md) | [513](/filings/0001193125-26-335003.md) | [370](/filings/0001193125-25-269436.md) | [443](/filings/0001193125-26-084144.md) | [331](/filings/0001193125-26-208893.md) | [329](/filings/0001193125-26-335003.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | [309](/filings/0001193125-26-084144.md) | [316](/filings/0001193125-26-084144.md) | [338](/filings/0001193125-26-084144.md) | [506](/filings/0001193125-26-084144.md) | [474](/filings/0001193125-26-084144.md) | [361](/filings/0001193125-26-084144.md) | [219](/filings/0001193125-26-084144.md) | [(29.1)](/filings/0001193125-26-084144.md) | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [121](/filings/0000950170-24-122239.md) | [132 d](/filings/0001193125-26-084144.md) | [127](/filings/0000950170-25-064412.md) | [139](/filings/0000950170-25-103971.md) | [128](/filings/0001193125-25-269436.md) | [164 d](/filings/0001193125-26-084144.md) | [134](/filings/0001193125-26-208893.md) | [138](/filings/0001193125-26-335003.md) | [91.9](/filings/0001193125-25-269436.md) | [128 d](/filings/0001193125-26-084144.md) | [109](/filings/0001193125-26-208893.md) | [108](/filings/0001193125-26-335003.md) |
| Operating income | $m | [(20.8)](/filings/0000950170-24-122239.md) | [24.6 d](/filings/0001193125-26-084144.md) | [34.9](/filings/0000950170-25-064412.md) | [(0.7)](/filings/0000950170-25-103971.md) | [22.2](/filings/0001193125-25-269436.md) | [162 d](/filings/0001193125-26-084144.md) | [(300)](/filings/0001193125-26-208893.md) | [116](/filings/0001193125-26-335003.md) | [(103)](/filings/0001193125-25-269436.md) | [(412) d](/filings/0001193125-26-084144.md) | [358](/filings/0001193125-26-208893.md) | [13.3](/filings/0001193125-26-335003.md) |
| Interest expense | $m | [5.2](/filings/0000950170-24-122239.md) | [(38.8) d](/filings/0001193125-26-084144.md) | [(4.2)](/filings/0000950170-25-064412.md) | [4.8](/filings/0000950170-25-103971.md) | [4.9](/filings/0001193125-25-269436.md) | [(32.3) d](/filings/0001193125-26-084144.md) | [(4.5)](/filings/0001193125-26-208893.md) | [(5.2)](/filings/0001193125-26-335003.md) | [1.9](/filings/0001193125-26-084144.md) | [(40.0) d](/filings/0001193125-26-084144.md) | [(21.7)](/filings/0001193125-26-208893.md) | [(21.5)](/filings/0001193125-26-335003.md) |
| Income tax | $m | [7.8](/filings/0000950170-24-122239.md) | [(5.3) d](/filings/0001193125-26-084144.md) | [5.3](/filings/0000950170-25-064412.md) | [7.1](/filings/0000950170-25-103971.md) | [0.4](/filings/0001193125-25-269436.md) | [12.7 d](/filings/0001193125-26-084144.md) | [64.0](/filings/0001193125-26-208893.md) | [(43.3)](/filings/0001193125-26-335003.md) | [(14.1)](/filings/0001193125-25-269436.md) | [4.6 d](/filings/0001193125-26-084144.md) | [12.2](/filings/0001193125-26-208893.md) | [3.1](/filings/0001193125-26-335003.md) |
| Net income | $m | [(40.9)](/filings/0000950170-24-122239.md) | [45.7 d](/filings/0001193125-26-084144.md) | [36.1](/filings/0001193125-26-084144.md) | [6.5](/filings/0001193125-26-084144.md) | [33.6](/filings/0001193125-26-084144.md) | [159](/filings/0001193125-26-084144.md) | [(448)](/filings/0001193125-26-335003.md) | [197](/filings/0001193125-26-335003.md) | [(50.6)](/filings/0001193125-26-084144.md) | [(412)](/filings/0001193125-26-084144.md) | [331](/filings/0001193125-26-335003.md) | [(4.9)](/filings/0001193125-26-335003.md) |
| Diluted EPS | $ per share | [(0.46)](/filings/0000950170-24-122239.md) | not reported | [0.37](/filings/0001193125-26-084144.md) | [0.07](/filings/0001193125-26-084144.md) | [0.34](/filings/0001193125-26-084144.md) | [1.50](/filings/0001193125-26-084144.md) | [(4.60)](/filings/0001193125-26-208893.md) | [1.89](/filings/0001193125-26-335003.md) | [(0.50)](/filings/0001193125-26-084144.md) | [(3.93)](/filings/0001193125-26-084144.md) | [2.88](/filings/0001193125-26-208893.md) | [(0.05)](/filings/0001193125-26-335003.md) |
| Basic EPS | $ per share | [(0.46)](/filings/0000950170-24-122239.md) | not reported | [0.38](/filings/0001193125-26-084144.md) | [0.07](/filings/0001193125-26-084144.md) | [0.35](/filings/0001193125-26-084144.md) | [1.65](/filings/0001193125-26-084144.md) | [(4.60)](/filings/0001193125-26-208893.md) | [2.01](/filings/0001193125-26-335003.md) | [(0.50)](/filings/0001193125-26-084144.md) | [(3.93)](/filings/0001193125-26-084144.md) | [3.15](/filings/0001193125-26-208893.md) | [(0.05)](/filings/0001193125-26-335003.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Cost of revenue: not reported
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [542](/filings/0000950170-24-122239.md) | [428](/filings/0001193125-26-084144.md) | [427](/filings/0000950170-25-064412.md) | [384](/filings/0000950170-25-103971.md) | [198](/filings/0001193125-25-269436.md) | [1,103](/filings/0001193125-26-084144.md) | [241](/filings/0001193125-26-208893.md) | [511](/filings/0001193125-26-335003.md) | [613](/filings/0001193125-25-269436.md) | [801](/filings/0001193125-26-335003.md) | [464](/filings/0001193125-26-208893.md) | [571](/filings/0001193125-26-335003.md) |
| Current assets | $m | [2,451](/filings/0000950170-23-057414.md) | [2,579](/filings/0000950170-25-029973.md) | [2,465](/filings/0000950170-24-051234.md) | [2,684](/filings/0000950170-24-092720.md) | [2,685](/filings/0000950170-24-122239.md) | [3,073](/filings/0001193125-26-084144.md) | [2,433](/filings/0000950170-25-064412.md) | [2,657](/filings/0000950170-25-103971.md) | [2,722](/filings/0001193125-25-269436.md) | [2,538](/filings/0001193125-26-335003.md) | [2,310](/filings/0001193125-26-208893.md) | [2,224](/filings/0001193125-26-335003.md) |
| Total assets | $m | [3,110](/filings/0000950170-23-057414.md) | [3,265](/filings/0000950170-25-029973.md) | [3,224](/filings/0000950170-24-051234.md) | [3,424](/filings/0000950170-24-092720.md) | [3,600](/filings/0000950170-24-122239.md) | [3,963](/filings/0001193125-26-084144.md) | [3,465](/filings/0000950170-25-064412.md) | [3,680](/filings/0000950170-25-103971.md) | [3,493](/filings/0001193125-25-269436.md) | [3,350](/filings/0001193125-26-335003.md) | [3,179](/filings/0001193125-26-208893.md) | [3,189](/filings/0001193125-26-335003.md) |
| Current liabilities | $m | [451](/filings/0000950170-23-057414.md) | [654](/filings/0000950170-25-029973.md) | [609](/filings/0000950170-24-051234.md) | [688](/filings/0000950170-24-092720.md) | [699](/filings/0000950170-24-122239.md) | [732](/filings/0001193125-26-084144.md) | [606](/filings/0000950170-25-064412.md) | [920](/filings/0000950170-25-103971.md) | [921](/filings/0001193125-25-269436.md) | [1,095](/filings/0001193125-26-335003.md) | [499](/filings/0001193125-26-208893.md) | [503](/filings/0001193125-26-335003.md) |
| Total liabilities | $m | [2,345](/filings/0000950170-23-057414.md) | [2,405](/filings/0000950170-25-029973.md) | [2,263](/filings/0000950170-24-051234.md) | [2,347](/filings/0000950170-24-092720.md) | [2,379](/filings/0000950170-24-122239.md) | [2,435](/filings/0001193125-26-084144.md) | [2,323](/filings/0000950170-25-064412.md) | [2,322](/filings/0000950170-25-103971.md) | [2,173](/filings/0001193125-25-269436.md) | [2,209](/filings/0001193125-26-335003.md) | [1,674](/filings/0001193125-26-208893.md) | [1,661](/filings/0001193125-26-335003.md) |
| Long-term debt | $m | [1,237](/filings/0000950170-23-057414.md) | [1,238](/filings/0000950170-25-029973.md) | [1,239](/filings/0000950170-24-051234.md) | [1,226](/filings/0000950170-24-092720.md) | [1,228](/filings/0000950170-24-122239.md) | [1,137](/filings/0001193125-26-084144.md) | not reported | not reported | [141](/filings/0001193125-26-084144.md) | [829](/filings/0001193125-26-335003.md) | [838](/filings/0001193125-26-208893.md) | [848](/filings/0001193125-26-335003.md) |
| Current portion of debt | $m | not reported | [105](/filings/0000950170-25-029973.md) | [106](/filings/0000950170-24-051234.md) | [91.5](/filings/0000950170-24-092720.md) | [91.6](/filings/0000950170-24-122239.md) | [0.0](/filings/0000950170-25-029973.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [764](/filings/0000950170-24-122239.md) | [859](/filings/0001193125-26-084144.md) | [961](/filings/0001193125-25-269436.md) | [1,077](/filings/0001193125-25-269436.md) | [1,221](/filings/0001193125-25-269436.md) | [1,528](/filings/0001193125-26-335003.md) | [1,190](/filings/0001193125-26-335003.md) | [1,405](/filings/0001193125-26-335003.md) | [1,320](/filings/0001193125-25-269436.md) | [1,141](/filings/0001193125-26-335003.md) | [1,505](/filings/0001193125-26-335003.md) | [1,528](/filings/0001193125-26-335003.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(115) d](/filings/0000950170-24-122239.md) | [(54.7) d](/filings/0001193125-26-084144.md) | [(242)](/filings/0000950170-25-064412.md) | [14.9 d](/filings/0000950170-25-103971.md) | [(70.7) d](/filings/0001193125-25-269436.md) | [92.0 d](/filings/0001193125-26-084144.md) | [(583)](/filings/0001193125-26-208893.md) | [261 d](/filings/0001193125-26-335003.md) | [(14.6) d](/filings/0001193125-25-269436.md) | [131 d](/filings/0001193125-26-084144.md) | [(203)](/filings/0001193125-26-208893.md) | [197 d](/filings/0001193125-26-335003.md) |
| Capital expenditure | $m | [29.7 d](/filings/0000950170-24-122239.md) | [19.0 d](/filings/0001193125-26-084144.md) | [32.4](/filings/0000950170-25-064412.md) | [29.2 d](/filings/0000950170-25-103971.md) | [37.3 d](/filings/0001193125-25-269436.md) | [38.1 d](/filings/0001193125-26-084144.md) | [43.7](/filings/0001193125-26-208893.md) | [31.8 d](/filings/0001193125-26-335003.md) | [22.9 d](/filings/0001193125-25-269436.md) | [3.6 d](/filings/0001193125-26-084144.md) | [2.1](/filings/0001193125-26-208893.md) | [0.6 d](/filings/0001193125-26-335003.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001193125-25-269436.md) | [0.0 d](/filings/0001193125-26-084144.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-269436.md) | [0.0 d](/filings/0001193125-26-084144.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [87.6](/filings/0000950170-23-057414.md) | [88.2](/filings/0000950170-24-051234.md) | [88.7](/filings/0000950170-24-092720.md) | [88.9](/filings/0000950170-24-122239.md) | [99.1](/filings/0000950170-25-064412.md) | [99.1](/filings/0000950170-25-103971.md) | [100](/filings/0001193125-25-269436.md) | [97.4](/filings/0001193125-26-208893.md) | [107](/filings/0001193125-26-335003.md) | [100](/filings/0001193125-25-269436.md) | [122](/filings/0001193125-26-208893.md) | [105](/filings/0001193125-26-335003.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 105,627,021 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335003.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.